siRNA nanodelivery systems in the treatment of skin Diseases: Research progress and clinical translation prospects.

BACKGROUND

Skin diseases affect approximately one-third of the global population. RNA interference (RNAi) technology, through the use of small interfering RNAs (siRNAs), enables precise silencing of pathogenic gene expression. However, clinical application of siRNA is hindered by the stratum corneum barrier of the skin and the inherent instability of siRNAs, which are prone to degradation.

OBJECTIVE

This review systematically summarizes the recent advances in siRNA nanodelivery systems for the treatment of psoriasis, skin cancer, chronic wounds, and skin fibrosis. It highlights the targeted intervention strategies, clinical research progress, and discusses the potential impact on pharmaceutical care and clinical translation.

METHODS

A comprehensive analysis was conducted on domestic and international literature regarding nanocarrier-mediated siRNA delivery to the skin. Therapeutic efficacy, safety profiles, and translational feasibility were critically evaluated.

RESULTS AND

CONCLUSION

In the field of psoriasis, siRNA-based nanodrugs targeting IL-17A and STAT3/TNF-α have entered clinical trials, demonstrating efficacy comparable to that of biologics. In skin cancer therapy, multi-targeted siRNA delivery systems have shown significant inhibition of tumor growth and metastasis. In chronic wound healing and skin fibrosis, siRNA nanotherapies have enabled precise regulation of tissue repair processes. Nonetheless, challenges such as large-scale manufacturing, batch-to-batch consistency, and comprehensive safety assessment remain. Future directions involve the integration of multifunctional delivery platforms and personalized treatment strategies, with accelerated clinical translation through multidisciplinary collaboration among academia, industry, and healthcare sectors.